SRRK news

Latest 2 stories · newest Sep 14, 2026

SRRK
FDA approves muscle-targeted treatment ISEMBYLD for SMA

Scholar Rock receives FDA approval for ISEMBYLD, the first muscle-targeted therapy for SMA patients receiving SMN2-targeted treatments, with the product rollout already underway. The approval is marked by positive clinical endpoints on motor function improvement, garnering significant market interes…

Regulatory Sep 14, 2026 sentiment +0.50 SEC filing ↗
SRRK
Scholar Rock files prospectus supplement for common stock offering.

Scholar Rock Holding Corp filed a July 7, 2026 Form 8-K to file a prospectus supplement for an offering of up to $200M in common stock, with legal counsel affirming the registration rights of the shares.

Offering Aug 6, 2026 sentiment 0.00 SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same SRRK feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/SRRK/newsSTART FREE